Effectiveness of bisphosphonate therapy in a community setting

Bone

Volumn 44, Issue 1, 2009, Pages 153-159

  Feldstein, Adrianne C ^a,b   Weycker, Derek ^c   Nichols, Gregory A ^a   Oster, Gerry ^c   Rosales, Gabriela ^a   Boardman, David L ^a   Perrin, Nancy ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b Northwest Permanente   (United States)

^c POLICY ANALYSIS INC PAI   (United States)

Author keywords

Bisphosphonate; Fracture risk; Post menopausal osteoporosis

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CHLORDIAZEPOXIDE; CLORAZEPATE; DIAZEPAM; DOXEPIN; ESTROGEN; FLURAZEPAM; IMIPRAMINE; PARATHYROID HORMONE[1-34]; PROTON PUMP INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; COHORT ANALYSIS; COMORBIDITY; DEMENTIA; DIABETES MELLITUS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; FRACTURE; HEALTH MAINTENANCE ORGANIZATION; HIP; HUMAN; IMAGING SYSTEM; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENTAL DISEASE; OSTEOARTHRITIS; OSTEOPOROSIS; PEPTIC ULCER; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RETROSPECTIVE STUDY; RISK; RISK REDUCTION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODELS; RESIDENCE CHARACTERISTICS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 57649099394     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.09.006     Document Type: Article

References (37)

1. Cummings S.R., and Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
2. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., and Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 22 (2007) 465-475
3. Hanley D.A., and Josse R.G. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 1. Introduction. CMAJ 155 (1996) 921-923
4. McCarus D.C. Fracture prevention in postmenopausal osteoporosis: a review of treatment options. Obstet. Gynecol. Surv. 61 (2006) 39-50
5. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., and Ensrud K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
6. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Palermo L., Prineas R., Rubin S.M., Scott J.C., Vogt T., Wallace R., Yates A.J., and LaCroix A.Z. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
7. Cranney A., Guyatt G., Griffith L., Wells G., Tugwell P., and Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 23 (2002) 570-578
8. Boonen S., Laan R.F., Barton I.P., and Watts N.B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos. Int. 16 (2005) 1291-1298
9. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., Hyldstrup L., Recknor C., Nordsletten L., Moore K.A., Lavecchia C., Zhang J., Mesenbrink P., Hodgson P.K., Abrams K., Orloff J.J., Horowitz Z., Eriksen E.F., and Boonen S. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357 (2007) 1799-1809
10. Ettinger B., Pressman A.R., Schein J., Chan J., Silver P., and Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J. Manag. Care Pharm. 4 (1998) 488-492
11. McCombs J.S., Thiebaud P., Laughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
12. Siris E.S., Harris S.T., Rosen C.J., Barr C.E., Arvesen J.N., Abbott T.A., and Silverman S. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin. Proc. 81 (2006) 1013-1022
13. Weycker D., Macarios D., Edelsberg J., and Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int. 17 (2006) 1645-1652
14. Huybrechts K.F., Ishak K.J., and Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38 (2006) 922-928
15. Caro J.J., Ishak K.J., Huybrechts K.F., Raggio G., and Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int. 15 (2004) 1003-1008
16. Adami S., Isaia G., Luisetto G., Minisola S., Sinigaglia L., Gentilella R., Agnusdei D., Iori N., and Nuti R. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J. Bone Miner. Res. 21 (2006) 1565-1570
17. Weycker D., Macarios D., Edelsberg J., and Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18 (2007) 271-277
18. Freeborn D.K., and Pope C. Promise and performance in managed care: the prepaid group practice model (1994), Johns Hopkins University Press, Baltimore, MD
19. Feldstein A.C., Elmer P.J., Orwoll E., Herson M., and Hillier T. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline. Arch. Intern. Med. 163 (2003) 2165-2172
20. National Osteoporosis Foundation. Physicians guide to prevention and treatment of osteoporosis (2000), National Osteoporosis Foundation, Washington, DC Ref Type: Report
21. Melton III L.J., Achenbach S.J., O'Fallon W.M., and Khosla S. Secondary osteoporosis and the risk of distal forearm fractures in men and women. Bone 31 (2002) 119-125
22. NIH Consensus Development Panel on Osteoporosis Prevention DaT. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
23. Seeley D.G., Browner W.S., Nevitt M.C., Genant H.K., Scott J.C., and Cummings S.R. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 115 (1991) 837-842
24. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., Cauley J., Black D., and Vogt T.M. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 332 (1995) 767-773
25. Schwartz A.V., and Sellmeyer D.E. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes. Expert. Opin. Drug Saf. 7 (2008) 69-78
26. Weng M.Y., and Lane N.E. Medication-induced osteoporosis. Curr. Osteoporos. Rep. 5 (2007) 139-145
27. Allport J. Incidence and prevalence of medication-induced osteoporosis: evidence-based review. Curr. Opin. Rheumatol. 20 (2008) 435-441
28. Tinetti M.E., Speechley M., and Ginter S.F. Risk factors for falls among elderly persons living in the community. N. Engl. J. Med. 319 (1988) 1701-1707
29. Schneeweiss S., Walker A.M., Glynn R.J., Maclure M., Dormuth C., and Soumerai S.B. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N. Engl. J. Med. 346 (2002) 822-829
30. Tosteson A.N., Melton III L.J., wson-Hughes B., Baim S., Favus M.J., Khosla S., and Lindsay R.L. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos. Int. 19 (2008) 437-447
31. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., Chesnut III C.H., Brown J., Eriksen E.F., Hoseyni M.S., Axelrod D.W., and Miller P.D. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
32. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., and Cummings S.R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356 (2007) 1809-1822
33. Laupacis A., and Mamdani M. Observational studies of treatment effectiveness: some cautions. Ann. Intern. Med. 140 (2004) 923-924
34. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., Nevitt M.C., Suryawanshi S., and Cummings S.R. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab. 85 (2000) 4118-4124
35. Wasnich R.D., Bagger Y.Z., Hosking D.J., McClung M.R., Wu M., Mantz A.M., Yates J.J., Ross P.D., Alexandersen P., Ravn P., Christiansen C., and Santora A.C. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 11 (2004) 622-630
36. Watts N.B., Chines A., Olszynski W.P., McKeever C.D., McClung M.R., Zhou X., and Grauer A. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos. Int. 19 3 (2008) 365-372 Electronic Publication 2007, Oct. 16
37. Ensrud K.E., Barrett-Connor E.L., Schwartz A., Santora A.C., Bauer D.C., Suryawanshi S., Feldstein A., Haskell W.L., Hochberg M.C., Torner J.C., Lombardi A., and Black D.M. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J. Bone Miner. Res. 19 (2004) 1259-1269